Financial Performance - Cash and cash equivalents increased to $12.5 million as of December 31, 2024, compared to $0.8 million as of December 31, 2023[3] - The net loss for the year ended December 31, 2024, was $(9.7) million, an improvement from a net loss of $(16.9) million in 2023, a decrease of $7.2 million[8] - Total revenue for 2024 was $500,000, compared to no revenue in 2023[17] Expenses - Research and development expenses were $0 for the year ended December 31, 2024, down from $1.4 million in 2023, reflecting the halt of all R&D activities[4] - General and administrative expenses decreased to $5.4 million in 2024 from $11.7 million in 2023, a reduction of $6.3 million[5] Assets and Liabilities - Total assets increased to $15.1 million as of December 31, 2024, from $11.6 million in 2023[15] - The company reported a right-of-use asset impairment loss of $5.7 million in 2024[17] Going Concern - The company has substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months[9] Strategic Alternatives - The company is exploring strategic alternatives to maximize stockholder value following a significant reduction in force and suspension of R&D activities[2] Shareholder Information - The weighted-average basic and diluted common shares outstanding increased to 2,043,278 in 2024 from 1,602,790 in 2023[17]
Exicure(XCUR) - 2024 Q4 - Annual Results